alexa Prospective, Longitudinal, Multicenter Observational Study of Long-term Treatment with Intramuscular Interferon β-1a of Patients with Clinically Isolated Syndrome at High Risk of Conversion
ISSN: 2155-9562

Journal of Neurology & Neurophysiology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Prospective, Longitudinal, Multicenter Observational Study of Long-term Treatment with Intramuscular Interferon β-1a of Patients with Clinically Isolated Syndrome at High Risk of Conversion

Hernández Miguel Ángel1*, Prieto, José María2, Arnal Carmen3, Sánchez Fernando4 and Izquierdo Guillermo5

1Hospital Universitario Ntra Sra de la Candelaria, Santa Cruz de Tenerife, Spain

2Hospital Clínico Universitario Santiago de Compostela, Santiago de Compostela, Spain

3Hospital Virgen de las Nieves, Granada, Spain

4Hospital Universitario Reina Sofía, Córdoba, Spain

5Hospital Universitario Virgen Macarena, Sevilla, Spain

Corresponding Author:
Hernandez MA
Hospital Universitario Ntra Sra de la Candelaria
Ctra del Rosario, 145. Unidad de Esclerosis Múltiple
2a Torre Norte. Servicio de Neurología 38010, Spain
Tel: +34 92 260 0664
E-mail: [email protected]

Received date: January 10, 2014; Accepted date: February 19, 2014; Published date: February 25, 2014

Citation: Hernández Ángel M, Prieto, María J, Carmen A, Fernando S, et al. (2014) Prospective, Longitudinal, Multicenter Observational Study of Long-term Treatment with Intramuscular Interferon β-1a of Patients with Clinically Isolated Syndrome at High Risk of Conversion. J Neurol Neurophysiol 5:193. doi:10.4172/2155-9562.1000193

Copyright: © 2014 Hernández, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Introduction: Early initiation of treatment with intramuscular (IM) interferon (IFN) β-1a in patients with a single
demyelinating event suggestive of multiple sclerosis (MS) has been shown to reduce the risk of a second event.
This study investigated the characteristics of patients with clinically isolated syndrome (CIS), conversion to clinically
definite MS and quality of life (QoL) in clinical practice.
Methods: Patients eligible for IM IFNβ-1a for CIS were followed for 4 years (1 visit every 6 months, 9 visits in
total). Disease progression was assessed using the Expanded Disability Status Scale (EDSS). The rate of conversion,
adverse events and laboratory parameters were reported. Patients were administered QoL questionnaires (Functional
Assessment of Multiple Sclerosis [FAMS] and EuroQol 5D [EQ-5D]).
Results: Thirty-four patients from 15 Spanish hospitals were included and 18 completed the study. The mean ±
SD age of the patients was 32.1 ± 9.08 years and 64% were women. At baseline, the mean EDSS was 0.94 ± 0.85.
During follow-up, mean EDSS ranged from 0.89-1.25 and 15 patients (45.5%) converted to CIS. The most common
adverse reaction was flu-like syndrome (55%). One patient discontinued treatment due to flu-like syndrome.
The mean score on the visual analogue scale of the FAMS and the EQ-5D remained constant throughout the
study (p>0.05 with respect to baseline).
Conclusions: The conversion rate was higher than in the immediate-treatment arm of CHAMPIONS study, which
could be expected due to differences in the patient population and delays in treatment initiation.
The added value of the present study lies in the prospective collection of data from the clinical practice in highrisk
CIS patients treated with IM IFNβ-1a in Spain. To our knowledge, this is the first study published with these
characteristics.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords